Navigation Links
Tiny genetic variation can predict ovarian cancer outcome
Date:12/5/2011

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

The findings, published in the journal Oncogene, provide new insights into the biology of a new class of cancer marker and suggest a genetic test may help guide the treatment of women with ovarian cancer.

"This gives us a way to identify which women are at highest risk for resistance to platinum chemotherapy, the standard treatment for ovarian cancer, and helps identify ovarian cancer patients with the worst outcomes," said Joanne Weidhaas, associate professor of therapeutic radiology and senior author of the study. "There just aren't many inherited gene variants than can do that."

Women who possess the biomarker identified by the Yale team a variant of the well-known KRAS oncogene are three times more resistant to standard platinum chemotherapy than women without the variant. Also, post-menopausal women with the variant are significantly more likely to die from ovarian cancer. About 12-15 percent of Caucasians and 6 percent of African-Americans are born with the variant of the gene, which helps regulate destruction of damaged cells. This variant is found in up to 25% of newly diagnosed ovarian cancer patients.

Although good alternatives to chemotherapy are not yet available for women with ovarian cancer and this variant, several drugs in development which target the KRAS gene and associated pathways have shown great promise, Weidhaas said.

Weidhaas is a co-founder of a company that has licensed intellectual property from Yale that has developed a diagnostic test based on the Kras-variant.

The biomarker intrigues scientists because it is a functional variant in an area of DNA that does not code for proteins. Instead this variant disrupts how a microRNA controls gene expression.

"This is a new paradigm," Weidhaas said.

Yale researchers have also found this microRNA variant of the KRAS gene is associated with an increased risk of developing breast cancer and lung cancer. Other researchers have found associations with poor outcome in colon as well as head and neck cancers.

In laboratory tests, researchers blocked the variant and significantly reduced growth of ovarian cancer cells. This suggests targeting the variant site may someday help treat cancer in these patients.


'/>"/>

Contact: Bill Hathaway
william.hathaway@yale.edu
203-432-1322
Yale University
Source:Eurekalert

Related medicine news :

1. Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments
2. Unlocking the genetic and molecular mystery of soft-tissue sarcoma
3. CU-Boulder led study of smoking twins points to growing influence of genetic factors
4. Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
5. Combination epigenetic therapy clinical trial results
6. Epigenetic therapy shows promise in hard-to-treat lung cancer
7. Breakthrough in understanding the genetics of high blood pressure
8. Possible Genetic Link to Autism Identified
9. Ohio State researchers design a viral vector to treat a genetic form of blindness
10. Study identifies genetic basis of human metabolic individuality
11. 23andMe discovers genetic variant that may protect those at risk for Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: